Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Jan;80(1):113-123.
doi: 10.1002/jpn3.12384. Epub 2024 Oct 16.

Efficacy of vedolizumab and ustekinumab in pediatric-onset inflammatory bowel disease: A real-world multicenter study

Soleynne Rébus  1 , Stéphanie Coopman  1 , Djamal Djeddi  2 , Audrey Vanrenterghem  2 , Claire Dupont  3   4 , Edouard Lacotte  3   4 , Delphine Ley  1   5
Affiliations
Multicenter Study

Efficacy of vedolizumab and ustekinumab in pediatric-onset inflammatory bowel disease: A real-world multicenter study

Soleynne Rébus et al. J Pediatr Gastroenterol Nutr. 2025 Jan.

Abstract

Objectives: Vedolizumab and ustekinumab are effective in inducing and maintaining corticosteroid-free clinical remission (CFR) in adult patients with inflammatory bowel disease (IBD). This study describes the efficacy and safety of vedolizumab and ustekinumab in pediatric IBD.

Methods: All patients ≤18 years of age with Crohn's disease (CD) or ulcerative colitis (UC) treated with vedolizumab or ustekinumab in three centers in Northern France were followed retrospectively. The primary outcome was CFR at Week 14 (W14).

Results: Twenty-five patients (9 CD, 16 UC) and 33 patients (28 CD, 5 UC) were started on vedolizumab and ustekinumab respectively between 2016 and 2021. All were previously treated with antitumor necrosis factor (TNF). The median time from diagnosis to treatment initiation was 21.0 (12.0-44.0) and 42.0 (22.0-73.5) months for vedolizumab and ustekinumab, respectively. Among vedolizumab-treated patients, 36% were in CFR at W14, including 22% in CD and 44% in UC. At W52, 56% were in CFR, including 33% in CD and 69% in UC. Among ustekinumab-treated patients, 49% were in CFR at W14, including 54% in CD and 20% in UC. At W52, 55% were in CFR, including 57% in CD and 40% in UC. There was a significant increase in median growth velocity between W0 and W52 of +2 SD in vedolizumab-treated patients (p = 0.0002). Four adverse events were reported during vedolizumab treatment, none for ustekinumab-treated patients.

Conclusions: Vedolizumab and ustekinumab appear to be effective in inducing and maintaining CFR in pediatric-onset IBD. Randomized controlled trials are needed to confirm these results.

Keywords: Crohn's disease; pediatrics; ulcerative colitis; ustekinumab; vedolizumab.

PubMed Disclaimer

References

REFERENCES

    1. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5A‐36A.
    1. Ghione S, Sarter H, Fumery M, et al. Dramatic increase in incidence of ulcerative colitis and Crohn's disease (1988‐2011): a population‐based study of French adolescents. Am J Gastroenterol. 2018;113(2):265‐272.
    1. Pigneur B, Seksik P, Viola S, et al. Natural history of Crohn's disease: comparison between childhood‐ and adult‐onset disease. Inflamm Bowel Dis. 2010;16(6):953‐961.
    1. Fumery M, Pariente B, Sarter H, et al. Long‐term outcome of pediatric‐onset Crohn's disease: a population‐based cohort study. Dig Liver Dis. 2019;51(4):496‐502.
    1. Kerur B, Machan JT, Shapiro JM, et al. Biologics delay progression of Crohn's disease, but not early surgery, in children. Clin Gastroenterol Hepatol. 2018;16(9):1467‐1473.

Publication types

Grants and funding

LinkOut - more resources